within Pharmacolibrary.Drugs.ATC.G;

model G03GA08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.4999999999999995e-06,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0060999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03GA08</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin (hCG) used primarily for the induction of final follicular maturation and ovulation during assisted reproductive technologies in women, and in the treatment of certain cases of male infertility. It is approved and used today as a substitute for urine-derived hCG.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult women following a single subcutaneous dose as typically administered in fertility treatments.</p><h4>References</h4><ol><li><p>Dhillon, S, &amp; Keating, GM (2008). Lutropin alfa. <i>Drugs</i> 68(11) 1529–1540. DOI:<a href=\"https://doi.org/10.2165/00003495-200868110-00005\">10.2165/00003495-200868110-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18627209/\">https://pubmed.ncbi.nlm.nih.gov/18627209</a></p></li><li><p>Loutradis, D, et al., &amp; Antsaklis, A (2009). Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility. <i>Current opinion in investigational drugs (London, England : 2000)</i> 10(4) 372–380. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19337959/\">https://pubmed.ncbi.nlm.nih.gov/19337959</a></p></li><li><p>van Schanke, A, et al., &amp; Sloot, WN (2010). Absorption, distribution, metabolism and excretion of corifollitropin alfa, a recombinant hormone with a sustained follicle-stimulating activity. <i>Pharmacology</i> 85(2) 77–87. DOI:<a href=\"https://doi.org/10.1159/000276546\">10.1159/000276546</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20110752/\">https://pubmed.ncbi.nlm.nih.gov/20110752</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03GA08;
